German watchdog approves Novo’s acquisition of Cardior Pharmaceuticals
The German cartel office has approved a deal by Denmark’s Novo Nordisk (NOVOb.CO) to purchase Cardior Pharmaceuticals, the regulator said in a statement on Thursday.
If you are not happy with the results below please do another search
The German cartel office has approved a deal by Denmark’s Novo Nordisk (NOVOb.CO) to purchase Cardior Pharmaceuticals, the regulator said in a statement on Thursday.
Cerevel Therapeutics reported positive data from its Phase III TEMPO-3 trial, showing that tavapadon can significantly improve symptom control in patients with Parkinson’s disease.
“Compliancy Group is the first of a cadre of HIPAA compliance resources vetted by the CHC to assist agencies working with healthcare covered entities to navigate the nuances of HIPAA, federal breach notification requirements, and evolving state privacy laws,” said Jim Potter, CHC executive director.
Peregrine Market Access, a full-service consulting, communications, and commercialization partner for the life sciences industry, announced the hiring of Mawais Farooqui as a data analyst and Lewis “Lewi” Clarke as an associate account executive.
Generic drugs present a notable absence of consensus among physicians within the realm of healthcare regarding patients’ choice between branded and generic alternatives. This lack of a clear stance among healthcare providers prompts an in-depth investigation into the myriad factors shaping their perspectives, including efficacy, patient preferences, and cost considerations.
Bayer continued its leadership shuffle not only at its world headquarters in Germany but at two U.S.–based subsidiaries. Yet most of the executive movement of late has been at smaller companies.
At this week’s American Academy of Neurology annual meeting, Amylyx provided additional data from its Phase III amyotrophic lateral sclerosis study showing the full extent of Relyvrio’s failure.
The trial results add to a growing body of clinical evidence that suggests GLP-1 drugs, which include popular treatments such as Lilly’s Mounjaro and Novo Nordisk’s Wegovy, have medical benefits beyond diabetes and weight loss.
Sage Therapeutics said it will stop development of its experimental drug to treat Parkinson’s disease after the treatment failed a mid-stage study, sending the company’s shares tumbling 36% before the bell.
Today the drugmaker said long-term data showed that its blockbuster shingles vaccine, Shingrix, had 79.7% efficacy in participants aged 50 years and above, six to 11 years after vaccination.